Loading...
XSHE
300267
Market cap963mUSD
Jul 10, Last price  
3.29CNY
1D
3.79%
1Q
-17.96%
Jan 2017
-74.79%
IPO
50.56%
Name

Hunan Er-Kang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300267 chart
P/E
P/S
5.84
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-12.25%
Revenues
1.16b
+2.04%
157,832,491363,933,848608,416,476834,858,6441,010,838,0171,370,358,4901,755,998,9152,705,821,6232,827,885,1902,354,485,5792,354,485,5782,744,341,0052,382,275,0092,235,302,7872,235,302,7871,870,540,8101,870,540,8101,783,118,7801,139,612,2751,162,909,633
Net income
-380m
L+1.73%
22,750,49066,462,150117,811,939151,906,924192,929,453288,288,648604,578,677795,351,361522,456,317216,579,339216,579,344158,755,207192,306,4240-791,202,02645,944,93045,944,933-195,322,350-373,371,430-379,817,624
CFO
261m
+56.85%
209,79810,181,90742,471,66475,733,19284,021,539174,221,200175,382,420518,955,781486,495,536687,211,143123,894,781445,815,848178,527,34192,683,406281,019,942148,420,737166,691,706261,460,359
Dividend
Jun 09, 20230.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Er-Kang Pharmaceutical Co., Ltd is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), completed drug formulations, and pharmaceutical excipients, serving both the Chinese domestic market and international clients. Its API portfolio features substances such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's principal finished medications include sulbenicillin sodium for injection and compound liquorice tablets. For conventional pharmaceutical excipients, it provides items like pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose. Furthermore, its advanced pharmaceutical excipient offerings encompass hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate along with its related product series. The firm was established in 2003 and is headquartered in Liuyang, China.
IPO date
Sep 27, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122019‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT